These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 9186373

  • 1. Protein kinase C mediated anti-proliferative glucocorticoid-sphinganine synergism in cultured Pollard III prostate tumor cells.
    Sosnowski J, Stetter-Neel C, Cole D, Durham JP, Mawhinney MG.
    J Urol; 1997 Jul; 158(1):269-74. PubMed ID: 9186373
    [Abstract] [Full Text] [Related]

  • 2. Spisulosine (ES-285) induces prostate tumor PC-3 and LNCaP cell death by de novo synthesis of ceramide and PKCzeta activation.
    Sánchez AM, Malagarie-Cazenave S, Olea N, Vara D, Cuevas C, Díaz-Laviada I.
    Eur J Pharmacol; 2008 Apr 28; 584(2-3):237-45. PubMed ID: 18343365
    [Abstract] [Full Text] [Related]

  • 3. Anti-proliferative effect of the kinase inhibitor K252a on human prostatic carcinoma cell lines.
    Delsite R, Djakiew D.
    J Androl; 1996 Apr 28; 17(5):481-90. PubMed ID: 8957691
    [Abstract] [Full Text] [Related]

  • 4. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
    Koike M, Koshizuka K, Kawabata H, Yang R, Taub HE, Said J, Uskokovic M, Tsuruoka N, Koeffler HP.
    Anticancer Res; 1999 Apr 28; 19(3A):1689-97. PubMed ID: 10470102
    [Abstract] [Full Text] [Related]

  • 5. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
    Murthy S, Agoulnik IU, Weigel NL.
    Prostate; 2005 Sep 01; 64(4):362-72. PubMed ID: 15754350
    [Abstract] [Full Text] [Related]

  • 6. Luteinizing hormone-releasing hormone agonist limits DU-145 prostate cancer growth by attenuating epidermal growth factor receptor signaling.
    Wells A, Souto JC, Solava J, Kassis J, Bailey KJ, Turner T.
    Clin Cancer Res; 2002 Apr 01; 8(4):1251-7. PubMed ID: 11948140
    [Abstract] [Full Text] [Related]

  • 7. Fibroblast growth factor-2 and TPA enhance prostate-cancer-cell proliferation and activate members of the Ras and PKC signal transduction pathways.
    Hrzenjak M, Shain SA.
    Recept Signal Transduct; 1997 Apr 01; 7(4):207-19. PubMed ID: 9633822
    [Abstract] [Full Text] [Related]

  • 8. C-Jun N-terminal kinase is required for phorbol ester- and thapsigargin-induced apoptosis in the androgen responsive prostate cancer cell line LNCaP.
    Engedal N, Korkmaz CG, Saatcioglu F.
    Oncogene; 2002 Feb 07; 21(7):1017-27. PubMed ID: 11850819
    [Abstract] [Full Text] [Related]

  • 9. Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity.
    Siu SW, Lau KW, Tam PC, Shiu SY.
    Prostate; 2002 Jul 01; 52(2):106-22. PubMed ID: 12111702
    [Abstract] [Full Text] [Related]

  • 10. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype.
    Hobisch A, Ramoner R, Fuchs D, Godoy-Tundidor S, Bartsch G, Klocker H, Culig Z.
    Clin Cancer Res; 2001 Sep 01; 7(9):2941-8. PubMed ID: 11555613
    [Abstract] [Full Text] [Related]

  • 11. Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis.
    Uslu R, Borsellino N, Frost P, Gárban H, Ng CP, Mizutani Y, Belldegrun A, Bonavida B.
    Clin Cancer Res; 1997 Jun 01; 3(6):963-72. PubMed ID: 9815772
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Protein kinase C is inhibited by bisphosphonates in prostate cancer PC-3 cells.
    Tatsuda Y, Iguchi K, Usui S, Suzui M, Hirano K.
    Eur J Pharmacol; 2010 Feb 10; 627(1-3):348-53. PubMed ID: 19903468
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
    Sweeney P, Karashima T, Kim SJ, Kedar D, Mian B, Huang S, Baker C, Fan Z, Hicklin DJ, Pettaway CA, Dinney CP.
    Clin Cancer Res; 2002 Aug 10; 8(8):2714-24. PubMed ID: 12171905
    [Abstract] [Full Text] [Related]

  • 19. Protein kinase C inhibitors alter neurotensin receptor binding and function in prostate cancer PC3 cells.
    Carraway RE, Hassan S, Dobner PR.
    Regul Pept; 2008 Apr 10; 147(1-3):96-109. PubMed ID: 18313772
    [Abstract] [Full Text] [Related]

  • 20. Up-regulation of p21(WAF1/CIP1) levels leads to growth suppression of prostate cancer cell lines.
    Sugibayashi R, Kiguchi Y, Shimizu T, Suzuki T, Hamada H, Takeda K.
    Anticancer Res; 2002 Apr 10; 22(2A):713-9. PubMed ID: 12014641
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.